Lubiprostone: a chloride channel activator.

Article Details

Citation

Copy to clipboard

Lacy BE, Levy LC

Lubiprostone: a chloride channel activator.

J Clin Gastroenterol. 2007 Apr;41(4):345-51.

PubMed ID

17413599 [ View in PubMed

]

Abstract

In January 2006 the Food and Drug Administration approved lubiprostone for the treatment of chronic constipation in men and women aged 18 and over. Lubiprostone is categorized as a prostone, a bicyclic fatty acid metabolite of prostaglandin E1. Lubiprostone activates a specific chloride channel (ClC-2) in the gastrointestinal (GI) tract to enhance intestinal fluid secretion, which increases GI transit and improves symptoms of constipation. This article reviews the role of chloride channels in the GI tract, describes the structure, function, and pharmacokinetics of lubiprostone, and discusses clinically important data on this new medication.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Lubiprostone	Chloride channel protein 2	Protein	Humans	Yes	Inducer	Details